Amgen likely win Enbrel patent appeal, but Novartis scored some points: analyst
Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but analysts figure Amgen still holds an edge. At an appeals hearing Wednesday, judges heard arguments from Amgen and Novartis’ Sandoz unit over patents protecting big-selling Enbrel until 2029. While Sandoz’s… Read More »